{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:48:28Z","timestamp":1792018108793,"version":"4.4.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2024\\u201300455804"],"award-info":[{"award-number":["RS-2024\\u201300455804"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.biopha.2025.118368","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T19:00:31Z","timestamp":1752778831000},"page":"118368","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Increased cellular uptake and proteasome inhibition of carfilzomib through the optimized self-nanoemulsifying drug delivery system"],"prefix":"10.1016","volume":"190","author":[{"given":"Taek-Seon","family":"Yun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Guk","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Suep","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3670-386X","authenticated-orcid":false,"given":"Hong-Ki","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheong-Weon","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118368_bib1","doi-asserted-by":"crossref","first-page":"11595","DOI":"10.3390\/ijms222111595","article-title":"Proteasome inhibitors and their pharmacokinetics, pharmacodynamics, and metabolism","volume":"22","author":"Wang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118368_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.740796","article-title":"Carfilzomib: a promising proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma","volume":"11","author":"Jayaweera","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2025.118368_bib3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/j.seminoncol.2018.01.004","article-title":"Proteasome inhibitors: structure and function","volume":"44","author":"Nunes","year":"2017","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.biopha.2025.118368_bib4","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1586\/ehm.12.26","article-title":"Role of carfilzomib in the treatment of multiple myeloma","volume":"5","author":"Khan","year":"2012","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.biopha.2025.118368_bib5","doi-asserted-by":"crossref","first-page":"9946","DOI":"10.1073\/pnas.1334037100","article-title":"Proteasome inhibitors disrupt the unfolded protein response in myeloma cells","volume":"100","author":"Lee","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2025.118368_bib6","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2025.118368_bib7","doi-asserted-by":"crossref","first-page":"739","DOI":"10.15252\/embj.201490736","article-title":"Reprogramming of human cancer cells to pluripotency for models of cancer progression","volume":"34","author":"Kim","year":"2015","journal-title":"EMBO J."},{"key":"10.1016\/j.biopha.2025.118368_bib8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.blre.2013.10.002","article-title":"Targeting the ubiquitin proteasome system in haematological malignancies","volume":"27","author":"Crawford","year":"2013","journal-title":"Blood Rev."},{"key":"10.1016\/j.biopha.2025.118368_bib9","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1073\/pnas.87.18.7071","article-title":"Abnormally high expression of proteasomes in human leukemic cells","volume":"87","author":"Kumatori","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2025.118368_bib10","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1182\/blood-2006-04-016360","article-title":"Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma","volume":"109","author":"Jakob","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2025.118368_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2018.03.002","article-title":"Next-generation proteasome inhibitors for cancer therapy","volume":"198","author":"Park","year":"2018","journal-title":"Transl. Res."},{"key":"10.1016\/j.biopha.2025.118368_bib12","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-13-0755","article-title":"US Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma","volume":"19","author":"Herndon","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118368_bib13","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2025.118368_bib14","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/1078155217735881","article-title":"Physicochemical stability of carfilzomib (Kyprolis\u00ae) containing solutions in glass vials, ready-to-administer plastic syringes and infusion bags over a 28-day storage period","volume":"25","author":"Kim","year":"2019","journal-title":"J. Oncol. Pharm. Pr."},{"key":"10.1016\/j.biopha.2025.118368_bib15","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1021\/acs.molpharmaceut.8b00270","article-title":"Enhanced glioblastoma targeting ability of carfilzomib enabled by a DA7R-modified lipid nanodisk","volume":"15","author":"Zhang","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2025.118368_bib16","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00280-013-2267-x","article-title":"A phase I\/II study of carfilzomib 2\u201310-min infusion in patients with advanced solid tumors","volume":"72","author":"Papadopoulos","year":"2013","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.biopha.2025.118368_bib17","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jconrel.2019.04.006","article-title":"Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation","volume":"302","author":"Park","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2025.118368_bib18","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40005-021-00532-0","article-title":"Pharmacokinetic aspects of the clinically used proteasome inhibitor drugs and efforts toward nanoparticulate delivery systems","volume":"51","author":"Kwon","year":"2021","journal-title":"J. Pharm. Invest."},{"key":"10.1016\/j.biopha.2025.118368_bib19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jconrel.2014.10.005","article-title":"Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivo","volume":"196","author":"Ashley","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2025.118368_bib20","article-title":"Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: anticancer efficacy and pharmacokinetic studies in mice","volume":"12","author":"Park","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2025.118368_bib21","article-title":"Polymeric micelles loaded with carfilzomib increase tolerability in a humanized bone marrow-like scaffold mouse model","volume":"2","author":"Varela-Moreira","year":"2020","journal-title":"Int. J. Pharm. X"},{"key":"10.1016\/j.biopha.2025.118368_bib22","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.xphs.2020.01.008","article-title":"Carfilzomib delivery by quinic acid-conjugated nanoparticles: discrepancy between tumoral drug accumulation and anticancer efficacy in a murine 4T1 orthotopic breast cancer model","volume":"109","author":"Jun","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2025.118368_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11095-020-02922-9","article-title":"Ternary polypeptide nanoparticles with improved encapsulation, sustained release, and enhanced in vitro efficacy of carfilzomib","volume":"37","author":"Agbana","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biopha.2025.118368_bib24","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jconrel.2022.10.041","article-title":"Size optimization of carfilzomib nanocrystals for systemic delivery to solid tumors","volume":"352","author":"Gadalla","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2025.118368_bib25","first-page":"775","article-title":"New oral anti-cancer drugs and medication safety","volume":"116","author":"Schlichtig","year":"2019","journal-title":"Dtsch. Arztebl. Int."},{"key":"10.1016\/j.biopha.2025.118368_bib26","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1080\/10717544.2022.2083724","article-title":"Self-emulsifying drug delivery systems: a novel approach to deliver drugs","volume":"29","author":"Salawi","year":"2022","journal-title":"Drug Deliv."},{"key":"10.1016\/j.biopha.2025.118368_bib27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.biopha.2004.02.001","article-title":"Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs","volume":"58","author":"Gursoy","year":"2004","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.biopha.2025.118368_bib28","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1021\/js970300n","article-title":"Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor","volume":"87","author":"Hauss","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2025.118368_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2019.109980","article-title":"Statistical approach for solidifying ticagrelor loaded self-microemulsifying drug delivery system with enhanced dissolution and oral bioavailability","volume":"104","author":"Na","year":"2019","journal-title":"Mater. Sci. Eng. C."},{"key":"10.1016\/j.biopha.2025.118368_bib30","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1021\/acs.molpharmaceut.9b00964","article-title":"Pharmacokinetic\/pharmacodynamic modeling to predict the antiplatelet effect of the ticagrelor-loaded self-microemulsifying drug delivery system in rats","volume":"17","author":"Na","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2025.118368_bib31","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijpharm.2003.12.028","article-title":"Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs","volume":"274","author":"Kang","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118368_bib32","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3390\/pharmaceutics13071103","article-title":"Pharmaceutical formulations with P-glycoprotein inhibitory effect as promising approaches for enhancing oral drug absorption and bioavailability","volume":"13","author":"Nguyen","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2025.118368_bib33","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.colsurfb.2018.03.034","article-title":"Role of self-emulsifying drug delivery systems in optimizing the oral delivery of hydrophilic macromolecules and reducing interindividual variability","volume":"167","author":"AboulFotouh","year":"2018","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.biopha.2025.118368_bib34","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1016\/S0169-409X(01)00182-X","article-title":"In vitro assessment of oral lipid based formulations","volume":"50","author":"Porter","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biopha.2025.118368_bib35","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ijpharm.2009.03.008","article-title":"Enhanced oral bioavailability of Coenzyme Q10 by self-emulsifying drug delivery systems","volume":"374","author":"Balakrishnan","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118368_bib36","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1208\/s12249-010-9385-0","article-title":"Preparation and bioavailability assessment of SMEDDS containing valsartan","volume":"11","author":"Dixit","year":"2010","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.biopha.2025.118368_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11051-014-2818-z","article-title":"Design, formulation, in vitro, in vivo, and pharmacokinetic evaluation of nisoldipine-loaded self-nanoemulsifying drug delivery system","volume":"17","author":"Krishnamoorthy","year":"2015","journal-title":"J. Nanopart. Res."},{"key":"10.1016\/j.biopha.2025.118368_bib38","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0022-3565(24)29270-3","article-title":"Rational use of in vitro P-glycoprotein assays in drug discovery","volume":"299","author":"Polli","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2025.118368_bib39","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1172\/JCI1269","article-title":"The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors","volume":"101","author":"Kim","year":"1998","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.biopha.2025.118368_bib40","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4103\/2230-973X.143123","article-title":"Development of self-microemulsifying drug delivery system and solid-self-microemulsifying drug delivery system of telmisartan","volume":"4","author":"Jaiswal","year":"2014","journal-title":"Int. J. Pharm. Invest."},{"key":"10.1016\/j.biopha.2025.118368_bib41","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1080\/01621459.2017.1289846","article-title":"Statistical significance and the dichotomization of evidence","volume":"112","author":"McShane","year":"2017","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.biopha.2025.118368_bib42","doi-asserted-by":"crossref","first-page":"S3292","DOI":"10.1016\/j.arabjc.2013.12.028","article-title":"Use of response surface methodology for optimization of fluoride adsorption in an aqueous solution by Brushite","volume":"10","author":"Mourabet","year":"2017","journal-title":"Arab. J. Chem."},{"key":"10.1016\/j.biopha.2025.118368_bib43","first-page":"776","article-title":"Linear regression analysis: part 14 of a series on evaluation of scientific publications","volume":"107","author":"Schneider","year":"2010","journal-title":"Dtsch. Arztebl. Int."},{"key":"10.1016\/j.biopha.2025.118368_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/cc2401","article-title":"Statistics review 7: Correlation and regression","volume":"7","author":"Bewick","year":"2003","journal-title":"Crit. Care"},{"key":"10.1016\/j.biopha.2025.118368_bib45","article-title":"Preparation and evaluation of extended release pellets of chiral molecules of s-metoprolol succinate by different technology","volume":"11","author":"Patel","year":"2017","journal-title":"Asian J. Pharm."},{"key":"10.1016\/j.biopha.2025.118368_bib46","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/DDDT.S95905","article-title":"Self-emulsifying drug delivery systems as a tool to improve solubility and bioavailability of resveratrol","author":"Balata","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.biopha.2025.118368_bib47","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jconrel.2023.08.024","article-title":"Pancreatic lipase digestion: the forgotten barrier in oral administration of lipid-based delivery systems?","volume":"362","author":"Zupan\u010di\u010d","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2025.118368_bib48","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1111\/j.2042-7158.2010.01107.x","article-title":"New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs","volume":"62","author":"M\u00fcllertz","year":"2010","journal-title":"J. Pharm. Pharm."},{"key":"10.1016\/j.biopha.2025.118368_bib49","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.3390\/molecules27154910","article-title":"Free linoleic acid and oleic acid reduce fat digestion and absorption in vivo as potent pancreatic lipase inhibitors derived from sesame meal","volume":"27","author":"Li","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2025.118368_bib50","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrd2197","article-title":"Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs","volume":"6","author":"Porter","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2025.118368_bib51","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1080\/00498250802050880","article-title":"Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions","volume":"38","author":"Elsby","year":"2008","journal-title":"Xenobiotica"},{"key":"10.1016\/j.biopha.2025.118368_bib52","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/jps.20017","article-title":"Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes","volume":"93","author":"Shono","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2025.118368_bib53","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1208\/s12249-009-9347-6","article-title":"Solid self-microemulsifying formulation for candesartan cilexetil","volume":"11","author":"Nekkanti","year":"2010","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.biopha.2025.118368_bib54","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1007\/s11095-013-1094-4","article-title":"In vitro lipolysis and intestinal transport of \u03b2-arteether-loaded lipid-based drug delivery systems","volume":"30","author":"Memvanga","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biopha.2025.118368_bib55","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1042\/bj20031253","article-title":"Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis","volume":"377","author":"Rejman","year":"2004","journal-title":"Biochem. J."},{"key":"10.1016\/j.biopha.2025.118368_bib56","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2174\/092986710790416290","article-title":"Development of nanoparticles for antimicrobial drug delivery","volume":"17","author":"Zhang","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118368_bib57","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","article-title":"The proteasome: a suitable antineoplastic target","volume":"4","author":"Adams","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2025.118368_bib58","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","article-title":"Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome","volume":"67","author":"Demo","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2025.118368_bib59","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1124\/jpet.115.226993","article-title":"Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines","volume":"355","author":"Ao","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2025.118368_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.biopha.2025.118368_bib61","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.addr.2016.04.025","article-title":"Challenges and strategies in anti-cancer nanomedicine development: an industry perspective","volume":"108","author":"Hare","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biopha.2025.118368_bib62","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4103\/2230-973X.96920","article-title":"Drug delivery systems: an updated review","volume":"2","author":"Tiwari","year":"2012","journal-title":"Int. J. Pharm. Invest."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225005621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225005621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:27:10Z","timestamp":1772753230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225005621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":62,"alternative-id":["S0753332225005621"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118368","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased cellular uptake and proteasome inhibition of carfilzomib through the optimized self-nanoemulsifying drug delivery system","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118368","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118368"}}